Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
SkinCure Oncology
AddedFeb 15, 2024
UpdatedJun 18, 2026
SkinCure Oncology

SkinCure Oncology

Private Equity

SkinCure Oncology: Comprehensive support for superficial radiation skin cancer therapy.

HQ
Burr Ridge, IL, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to provide comprehensive support for superficial radiation therapy (SRT) in skin cancer treatment, SkinCure Oncology focuses on offering an alternative to traditional Mohs surgery. The company aims to enhance patient care and expand treatment options through the use of image-guided SRT technology. Their services are designed to support dermatology practices in integrating this advanced treatment method, thereby improving patient outcomes and practice growth.

SkinCure Oncology has established itself as a significant player in the dermatology field by partnering with numerous medical practices across the country. Notable investors and affiliated individuals include experts in oncology and dermatology who advocate for innovative cancer treatment methods. The company’s key achievements include widespread adoption of their SRT technology, which has positively impacted patient care by providing a non-invasive alternative to surgery. Overall, SkinCure Oncology has made a substantial impact on the skin cancer treatment landscape by promoting safer, more effective therapeutic options.

SkinCure Oncology - Quick Facts

When was SkinCure Oncology founded?

SkinCure Oncology was founded in 2016.

Where is SkinCure Oncology's headquarters located?

SkinCure Oncology's headquarters is located in Burr Ridge, IL, US.

When was SkinCure Oncology's last funding round?

SkinCure Oncology's most recent funding round was for $30M (USD) in September 2019.

How much has SkinCure Oncology raised to-date?

As of Sep 24, 2019, SkinCure Oncology has raised a total of $30M (USD).

How many employees does SkinCure Oncology have?

SkinCure Oncology has 227 employees as of Feb 5, 2024.

SkinCure Oncology - Classification

Industry
  • Professional Service Companies
Ownership
  • Private
Technology
  • Telemedicine
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Cancer Treatment
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 7 more industry codes
NAICS
  • 621000Ambulatory Health Care Services
  • 621400Outpatient Care Centers
  • 621490Other Outpatient Care Centers
  • 621491HMO Medical Centers
  • 623000Nursing and Residential Care Facilities
SIC
  • 8010Offices And Clinics Of Doctors Of Medicine
  • 8011Offices And Clinics Of Doctors Of Medicine